aTyr Pharma
ATYR
56 hedge funds and large institutions have $84.3M invested in aTyr Pharma in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 5 closing their positions.
960% more call options, than puts
Call options by funds: $53K | Put options by funds: $5K
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
19% more funds holding
Funds holding: 47 → 56 (+9)
12% more capital invested
Capital invested by funds: $75.1M → $84.3M (+$9.18M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.58% less ownership
Funds ownership: 69.73% → 63.15% (-6.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.85M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$633K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$610K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$266K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$253K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.82M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.6M |
| 3 |
SCM
Superstring Capital Management
New York
|
-$488K |
| 4 |
CC
Checkpoint Capital
San Francisco,
California
|
-$382K |
| 5 |
Renaissance Technologies
New York
|
-$263K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
National Bank of Canada
Montreal,
Quebec, Canada
| $630 | +$651 | +358 | New |
|
|
PP
52
PFS Partners
Mine Hill,
New Jersey
| $599 | – | – | – |
|
|
S
53
Sachetta
Lynnfield,
Massachusetts
| $264 | – | – | – |
|
|
CSC
54
Caldwell Sutter Capital
Sausalito,
California
| $92 | – | – | – |
|
|
SIS
55
Strategic Investment Solutions
Orland Park,
Illinois
| $14 | – | – | – |
|
56
Morgan Stanley
New York
| $2 | – | – | – |
|
|
SCM
57
Superstring Capital Management
New York
| – | -$488K | -313,028 | Closed |
|
|
SA
58
Sanctuary Advisors
Indianapolis,
Indiana
| – | -$45.9K | -29,207 | Closed |
|
|
CSS
59
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$25.7K | -16,485 | Closed |
|
60
Verition Fund Management
Greenwich,
Connecticut
| – | -$19.8K | -12,675 | Closed |
|
|
CC
61
Cypress Capital
Franklin,
Tennessee
| – | -$312 | -200 | Closed |
|
ATYR Hedge Fund Activity: Q3 2024 in Review
56 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2024, worth a combined $84.3M — up 12% from $75.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ATYR positions and 5 closed out — a net gain of 9 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.85M. The largest seller was Logos Global Management, cutting an estimated $1.82M.
- 56 institutional investors held aTyr Pharma (ATYR) as of Q3 2024, up from 47 in Q2 2024.
- Funds reported $84.3M of aTyr Pharma stock for Q3 2024, up 12% quarter-over-quarter.
- 14 funds opened new aTyr Pharma positions in Q3 2024 and 5 closed out, a net change of +9 holders.
- The largest aTyr Pharma buyer in Q3 2024 was Fidelity Investments, an estimated $1.85M added.
- The largest aTyr Pharma seller in Q3 2024 was Logos Global Management, an estimated $1.82M sold.
Based on aggregated 13F filings for Q3 2024.